Kewaunee Scientific reported fourth-quarter fiscal 2026 sales of $71.4 million, down 7.5% from $77.1 million a year earlier, as project timing weighed on results. Net earnings fell to $3.4 million from $4.9 million, with diluted earnings per share declining to $1.13 from $1.63. The Lab Products Group, one of two reportable segments, posted sales of $54.4 million, down 2% year over year, while the International segment saw a steeper 21.3% decline to $17 million, primarily due to shipment timing for Middle East projects. For the full fiscal year, however, revenues rose 17.3% to $282 million, and the company highlighted a strengthened balance sheet with long-term debt reduced to $40.9 million from $60.7 million. CEO Thomas D. Hull III described fiscal 2026 as an excellent year despite a challenging operating environment, citing progress in integrating Nu Aire and meaningful debt reduction.
Kewaunee Scientific CorporationQ4 sales fell 7.5% and earnings declined, missing prior year results.